Compare
Damora Therapeutics, Inc. vs Nature's Sunshine Products Inc vs Phathom Pharmaceuticals, Inc. vs Assembly Biosciences, Inc.
| Latest fiscal year | Damora Therapeutics, Inc. DMRA | Nature's Sunshine Products Inc NATR | Phathom Pharmaceuticals, Inc. PHAT | Assembly Biosciences, Inc. ASMB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $480.14M | $175.11M | $72.30M |
| Revenue growth (YoY) | n/a | +5.7% | +216.9% | +153.5% |
| Gross margin | n/a | 72.4% | 87.1% | n/a |
| Operating margin | n/a | 5.2% | -91.4% | -16.8% |
| Net margin | n/a | 4.3% | -126.3% | -8.5% |
| Net income | -$209.84M | $20.45M | -$221.25M | -$6.12M |
| EPS (Diluted) | $3.98 | $1.06 | -$3.03 | -$0.55 |
| Operating cash flow | -$6.73M | $35.32M | -$166.78M | -$41.09M |
| Free cash flow | n/a | $28.84M | -$167.00M | -$41.16M |
| Cash & equivalents | $257.62M | $93.89M | $129.97M | $58.45M |
| Total assets | $260.53M | $261.15M | $259.15M | $257.59M |
| Total liabilities | $20.15M | $99.59M | $697.32M | $50.84M |
| Shareholders' equity | $240.38M | $161.55M | -$438.17M | $206.75M |
| Return on year-end equity | -87.3% | 12.7% | n/a | -3.0% |
| Shares outstanding | 1.60M | 17.51M | 71.42M | 15.86M |
Revenue, most recent five fiscal years
| Fiscal year | Damora Therapeutics, Inc. | Nature's Sunshine Products Inc | Phathom Pharmaceuticals, Inc. | Assembly Biosciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | $480.14M Ended 2025-12-31 | $175.11M Ended 2025-12-31 | $72.30M Ended 2025-12-31 |
| 1 year earlier | n/a | $454.36M Ended 2024-12-31 | $55.25M Ended 2024-12-31 | $28.52M Ended 2024-12-31 |
| 2 years earlier | n/a | $445.32M Ended 2023-12-31 | $682.0K Ended 2023-12-31 | $7.16M Ended 2023-12-31 |
| 3 years earlier | n/a | $421.91M Ended 2022-12-31 | $0 Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $444.08M Ended 2021-12-31 | n/a | $6.25M Ended 2021-12-31 |